Cardiff Oncology, Inc. (CRDF) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Beyond Air, Inc.

Milestone Scientific, Inc.

InspireMD, Inc.

Prenetics Global Ltd.

Wrap Technologies, Inc.

VolitionRX Ltd.

Asensus Surgical, Inc.

Perspective Therapeutics, Inc.

Cardiff Oncology, Inc.

CollPlant Biotechnologies Ltd.

Cue Health, Inc.

Why is Cardiff Oncology, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Cardiff Oncology, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Cardiff Oncology, Inc.

-59.93%

-0.69

84.99%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

4.06%

EBIT Growth (5y)

-189.20%

EBIT to Interest (avg)

-38.43

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.12

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

59.25%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.33

EV to EBIT

-0.99

EV to EBITDA

-1.01

EV to Capital Employed

-3.97

EV to Sales

48.39

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-101.02%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET PROFIT(HY)

Higher at USD -19.56 MM

DEBT-EQUITY RATIO (HY)

Lowest at -130.83 %

DEBTORS TURNOVER RATIO(HY)

Highest at 1.76 times

-2What is not working for the Company

RAW MATERIAL COST(Y)

Grown by 299.4% (YoY

CASH AND EQV(HY)

Lowest at USD 104.36 MM

Here's what is working for Cardiff Oncology, Inc.

Net Profit

Higher at USD -19.56 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debt-Equity Ratio

Lowest at -130.83 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 1.76 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Cardiff Oncology, Inc.

Cash and Eqv

Lowest at USD 104.36 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 299.4% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales